A Comparison of Short- and Long-Term Therapeutic Outcomes of Infliximab- versus Tacrolimus-Based Strategies for Steroid-Refractory Ulcerative Colitis

Figure 4

Kaplan-Meier plots for relapse-free survival. The relapse-free survival rate at 3, 6, 12, and 18 months was 100%, 97%, 83%, and 83% in the infliximab group and 90%, 57%, 37%, and 37% in the tacrolimus group , respectively. The relapse-free survival rate was significantly higher in the infliximab group than in the tacrolimus group (; log-rank test).